文献速递心脑血管急症

低剂量利伐沙班对比阿司匹林联合P2Y12抑制剂治疗急性冠脉综合征的临床显著出血:GEMINI-ACS-1双盲多中心随机试验

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
PubMed 文献 · Lancet · 2017-03-18
一句话结论急性冠脉综合征患者用低剂量利伐沙班替代阿司匹林联合P2Y12抑制剂,TIMI非CABG临床显著出血与阿司匹林方案相似(5% vs 5%,HR 1.09)。

GEMINI-ACS-1是在21个国家371个中心进行的双盲随机试验,纳入3037例急性冠脉综合征患者,在就诊10天内随机接受利伐沙班2.5 mg每日两次或阿司匹林100 mg每日一次,联合氯吡格雷或替格瑞洛(由研究者选择),治疗至少180天。主要终点为至第390天的TIMI非CABG临床显著出血(主要、次要或需医疗关注),结果利伐沙班组80/1519(5%)vs 阿司匹林组74/1518(5%),HR 1.09(95%CI 0.80-1.50),P=0.5840,两组相似。作者认为双通路抗栓方案出血风险与阿司匹林联合P2Y12抑制剂相似,需更大样本量试验才能明确评估该方案的疗效和安全性。

要点

  • 急性冠脉综合征患者以利伐沙班2.5 mg每日两次替代阿司匹林100 mg每日一次联合P2Y12抑制剂,TIMI非CABG临床显著出血相似(80/1519 [5%] vs 74/1518 [5%],HR 1.09,95%CI 0.80-1.50,P=0.5840)。
  • 该方案在就诊10天内启动,治疗至少180天,中位治疗291天(IQR 239-354)。
  • P2Y12抑制剂(氯吡格雷或替格瑞洛)由研究者在随机化前选择,非随机分组:替格瑞洛层1704例(56%),氯吡格雷层1333例(44%)。
  • 作者认为需更大样本量、足够把握度的试验才能明确评估该双通路抗栓方案的疗效和安全性。

适用人群与场景

  • 年龄大于18岁、因不稳定型心绞痛、非ST段抬高型心肌梗死(NSTEMI)或ST段抬高型心肌梗死(STEMI)入院,心肌生物标志物阳性,并有缺血性心电图改变或血管造影发现动脉粥样硬化性罪犯病变的患者。
  • 在急性冠脉综合征事件入院后10天内随机化,随机化时按计划使用的背景P2Y12抑制剂(氯吡格雷或替格瑞洛)分层。

处置流程与药物剂量

  • 在入院后10天内以1:1随机分配接受利伐沙班2.5 mg每日两次或阿司匹林100 mg每日一次,双盲治疗至少180天。
  • 联合使用氯吡格雷或替格瑞洛,由研究者在随机化前根据偏好选择,试验期间不随机。

研究设计与关键结果

  • 双盲、多中心、随机试验,在21个国家371个临床中心进行,共随机3037例急性冠脉综合征患者:阿司匹林组1518例,利伐沙班组1519例。
  • 主要终点为至第390天的TIMI非CABG临床显著出血(主要、次要或需医疗关注),利伐沙班组80/1519(5%)vs 阿司匹林组74/1518(5%),HR 1.09(95%CI 0.80-1.50),P=0.5840,两组相似。
  • 替格瑞洛层1704例(56%),氯吡格雷层1333例(44%);中位治疗时间291天(IQR 239-354)。

证据类型、等级与局限

  • 证据类型:双盲、多中心、随机对照试验(GEMINI-ACS-1)。
  • 作者结论:低剂量利伐沙班联合P2Y12抑制剂的双通路抗栓方案与阿司匹林联合P2Y12抑制剂的临床显著出血风险相似;需更大样本量、足够把握度的试验才能明确评估该方案的疗效和安全性。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对于急性冠脉综合征患者,以低剂量利伐沙班(2.5 mg每日两次)替代阿司匹林联合P2Y12抑制剂时,TIMI非CABG临床显著出血风险与阿司匹林100 mg每日一次联合P2Y12抑制剂相似(5% vs 5%,HR 1.09,95%CI 0.80-1.50)。
  • 作者认为该双通路抗栓方案的疗效和安全性需更大样本量、足够把握度的试验才能明确评估。

指南或共识出处

  • GEMINI-ACS-1试验,ClinicalTrials.gov注册号NCT02293395,发表于Lancet。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding. The safety of a dual pathway antithrombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor has not been assesssed in acute coronary syndromes. We aimed to assess rivaroxaban 2·5 mg twice daily versus aspirin 100 mg daily, in addition to clopidogrel or ticagrelor (chosen at investigator discretion before randomisation), for patients with acute coronary syndromes started within 10 days after presentation and continued for 6-12 months.

METHODS: In this double-blind, multicentre, randomised trial (GEMINI-ACS-1) done at 371 clinical centres in 21 countries, eligible patients were older than 18 years with unstable angina, non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI), with positive cardiac biomarkers and either ischaemic electrocardiographic changes or an atherosclerotic culprit lesion identified during angiography. Participants were randomly assigned (1:1) within 10 days after admission for the index acute coronary syndromes event to either aspirin or rivaroxaban based on a computer-generated randomisation schedule. Randomisation was balanced by using randomly permuted blocks with size of four and was stratified based on the background P2Y12 inhibitor (clopidogrel or ticagrelor) intended to be used at the time of randomisation. Investigators and patients were masked to treatment assignment. Patients received a minimum of 180 days of double-blind treatment with rivaroxaban 2·5 mg twice daily or aspirin 100 mg daily. The choice of clopidogrel or ticagrelor during trial conduct was not randomised and was based on investigator preference. The primary endpoint was thrombolysis in myocardial infarction (TIMI) clinically significant bleeding not related to coronary artery bypass grafting (CABG; major, minor, or requiring medical attention) up to day 390. Primary analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT02293395.

FINDINGS: Between April 22, 2015, and Oct 14, 2016, 3037 patients with acute coronary syndromes were randomly assigned; 1518 to receive aspirin and 1519 to receive rivaroxaban. 1704 patients (56%) were in the ticagrelor and 1333 (44%) in the clopidogrel strata. Median duration of treatment was 291 days (IQR 239-354). TIMI non-CABG clinically significant bleeding was similar with rivaroxaban versus aspirin therapy (total 154 patients [5%]; 80 participants [5%] of 1519 vs 74 participants [5%] of 1518; HR 1·09 [95% CI 0·80-1·50]; p=0·5840).

INTERPRETATION: A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor. A larger, adequately powered trial would be required to definitively assess the efficacy and safety of this approach.

FUNDING: Janssen Research & Development and Bayer AG.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017. PMID: 28325638. doi:10.1016/S0140-6736(17)30751-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。